Your browser doesn't support javascript.
loading
Dosimetric parameters and safety analysis of 3D-printing non-coplanar template-assisted interstitial brachytherapy for non-centrally recurrent cervical cancer.
Wang, Cong; Cheng, Yan; Song, Yadong; Lei, Jia; Li, Yiqian; Li, Xia; Shi, Huirong.
Affiliation
  • Wang C; Department of Gynecological Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Cheng Y; Department of Gynecological Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Song Y; Department of Gynecological Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Lei J; Department of Gynecological Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li Y; Department of Gynecological Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li X; Department of Gynecological Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Shi H; Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol ; 13: 1174470, 2023.
Article de En | MEDLINE | ID: mdl-37954084
ABSTRACT

Introduction:

The prognosis of patients with non-central recurrent cervical cancer (NRCC) remains poor, and treatment options are limited. We aimed to explore the accuracy and safety of the 3D-printed non-coplanar template (3D-PNCT)-assisted 192Ir interstitial brachytherapy (ISBT) in the treatment of NRCC. Material and

methods:

A total of 36 patients with NRCC who received 3D-PNCT-guided 192Ir ISBT in the First Affiliated Hospital of Zhengzhou University from January 2021 to July 2022 were included in this study. There were 36 3D-PNCTs that were designed and printed. The prescribed dose was 30-36 Gy, divided into five to six times, once a week. To evaluate whether the actual parameters were consistent with the preoperative design, the dosimetric parameters of pre- and postoperative treatment plans were compared, including dose of 90% high-risk clinical target volume (HR-CTV D90), volume percentage of 100% and 150% prescribed dose V100% and V150%, homogeneity index (HI), conformal index (CI), external index (EI), and dose received by 2 cm3 (D2cm3) of the rectum, colon, bladder, and ileum. The safety parameters including occurrence of bleeding, infection, pain, radiation enteritis, and radiation cystitis within 3 months after operation were recorded.

Results:

All patients successfully completed the treatment and achieved the goals of the preoperative plan. There was no significant difference in the accuracy (HRCTVD90, V100%, EI, CI, and HI) and safety (D2cm3 of rectum, colon, bladder, and ileum) parameters of the postoperative plan compared with the preoperative plan (all p>0.05). Major side effects included bleeding at the puncture site (13.9%), postoperative pain (8.3%), acute radiation cystitis (13.9%), and radiation enteritis (19.4%). There were no serious perioperative complications and no grade 3-4 acute radiotherapy side effects.

Conclusion:

3D-PNCT-assisted 192Ir ISBT can be accurately and safely applied in the treatment of patients with NRCC.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Oncol Année: 2023 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Oncol Année: 2023 Type de document: Article Pays d'affiliation: Chine